ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Celgene continues dealmaking via agreements with Kyn Therapeutics, Obsidian Therapeutics
January 21, 2019Under the first agreement, Celgene will make an upfront cash payment of $80 million to Kyn, whilst also making an equity investment in the company. In return, Celgene will gain exclusive options to globally license Kyn's kynurenine-degrading enzyme and ar
Pharma Sources Insight January 2025
